The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Roche
Research Funding - Novartis
 
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; MSD; Novartis; Roche
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Aiwu Ruth He
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Li-Tzong Chen
Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - Celgene; Ministry of Health and Welfare Taiwan; Ministry of Science and Technology, Taiwan; Novartis; OBI Pharma; Pfizer; Polaris; SynCoreBio; TTY Biopharm
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Syneos Health/Immunocore (Inst); Taiho Pharmaceutical (Inst)
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Jin Won Kim
No Relationships to Disclose
 
Thatthan Suksombooncharoen
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Novartis; Roche/Genentech
 
Myung Ah Lee
No Relationships to Disclose
 
Masayuki Kitano
Honoraria - EA Pharma
Research Funding - Abbvie (Inst); Takeda (Inst)
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Vincerx Pharma (Inst)
 
Mohamed Bouattour
Honoraria - Bayer Schering Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; Sirtex Medical
Speakers' Bureau - Bayer; Roche; SIRTEX Medical
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche
 
Suebpong Tanasanvimon
No Relationships to Disclose
 
Renata Zaucha
No Relationships to Disclose
 
Antonio Avallone
No Relationships to Disclose
 
Juan Cundom
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche; Takeda
 
Nana Rokutanda
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Gordon Cohen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; Aptitude Health; AstraZeneca; Baxter; Cantargia AB; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Wren Laboratories; Zymeworks
Speakers' Bureau - Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER
Travel, Accommodations, Expenses - Lilly; Nucana; Roche